裂解酶CF-296联合达托霉素或万古霉素抗金黄色葡萄球菌小鼠大腿感染模型疗效评估
本研究在中性粒细胞减少小鼠大腿感染模型中评估裂解酶CF-296单用及联合达托霉素或万古霉素对8株金黄色葡萄球菌(1株MSSA、7株MRSA)的疗效。CF-296单药呈剂量依赖性杀菌,联合亚治疗剂量达托霉素或万古霉素较单用抗生素显著增强杀菌并呈剂量反应,多数剂量下实现≥1 log10 cfu/thigh下降。
要点
- CF-296单药对MSSA和MRSA分离株呈剂量依赖性杀菌。
- CF-296联合达托霉素或万古霉素较单用抗生素增强杀菌并呈剂量反应。
- 多数联合剂量实现≥1 log10 cfu/thigh细菌下降。
核心结论
- 与标准治疗抗生素(达托霉素或万古霉素)相比,加入CF-296产生稳健且增强的抗菌剂量反应,多数剂量实现≥1 log10 cfu/thigh下降,提示CF-296辅助治疗MSSA和MRSA感染的潜在作用。
研究设计与样本
- 中性粒细胞减少小鼠大腿感染模型,研究8株金黄色葡萄球菌(1株MSSA、7株MRSA)。
- CF-296单药静脉给药5个剂量(0.5–50 mg/kg);联合治疗为亚治疗剂量达托霉素或万古霉素单用,或联合上述5个CF-296剂量。
主要发现
- 相对起始接种量(5.80 ± 0.31 log10 cfu/thigh),载体对照组8株菌细菌密度增加+2.49 ± 0.98。
- 相对24小时对照,CF-296单药随剂量增加杀菌范围为-0.22 ± 0.87至-2.01 ± 1.71 log10 cfu/thigh。
- 达托霉素和万古霉素相对24小时对照分别减少细菌-1.36 ± 0.77和-1.37 ± 1.01 log10 cfu/thigh。
- CF-296(0.5–50 mg/kg)联合达托霉素较单用达托霉素增强剂量反应,杀菌范围-0.69至-2.13 log10 cfu/thigh。
- CF-296联合万古霉素较单用万古霉素细菌减少范围-1.37至-2.29 log10 cfu/thigh。
临床怎么用
- 结果支持CF-296作为辅助治疗与达托霉素或万古霉素联用对抗MSSA和MRSA的进一步临床前开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: CF-296 is a lysin in pre-clinical development for the treatment of MSSA and MRSA infections, used in addition to standard-of-care (SOC) antibiotics. We evaluated the efficacy of CF-296 alone and in addition to daptomycin or vancomycin against Staphylococcus aureus in the neutropenic mouse thigh infection model. METHODS: Eight isolates (one MSSA and seven MRSA) were studied. Mice were administered five CF-296 monotherapy doses ranging from 0.5 to 50 mg/kg intravenously. To assess adjunctive therapy, mice received sub-therapeutic daptomycin alone, sub-therapeutic vancomycin alone, or the five CF-296 doses in addition to either daptomycin or vancomycin. RESULTS: Relative to starting inoculum (5.80 ± 0.31 log10 cfu/thigh), bacterial density in vehicle controls increased by +2.49 ± 0.98 across all eight strains. Relative to 24 h controls, a dose-response in bacterial killing (range -0.22 ± 0.87 to -2.01 ± 1.71 log10 cfu/thigh) was observed with increasing CF-296 monotherapy against the eight isolates. Daptomycin and vancomycin resulted in -1.36 ± 0.77 and -1.37 ± 1.01 log10 cfu/thigh bacteria reduction, respectively, relative to 24 h controls. Escalating CF-296 exposures (0.5-50 mg/kg) in addition to daptomycin resulted in an enhanced dose-response, ranging from bacterial killing of -0.69 to -2.13 log10 cfu/thigh, relative to daptomycin alone. Similarly, in addition to vancomycin, escalating CF-296 exposures resulted in bacterial reduction ranging from -1.37 to -2.29 log10 cfu/thigh, relative to vancomycin alone. CONCLUSIONS: Relative to SOC antibiotics (daptomycin or vancomycin), addition of CF-296 resulted in robust and enhanced antibacterial dose-response, achieving ≥1 log10 cfu/thigh decrease across most doses, highlighting a potential role for CF-296 adjunctive therapy against MSSA and MRSA isolates.
引用
- Asempa TE, DeRosa NA, Cassino C, et al. Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model. J Antimicrob Chemother. 2021. PMID: 34223628. doi:10.1093/jac/dkab206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。